FDA approves OMIDRIA for use in pediatric patients

Omeros secures FDA approval of OMIDRIA for use in pediatric patients

Omeros jumps after detailing FDA meeting on IgA nephropathy program. See Stockwinners.com for details
Omeros secures FDA approval of OMIDRIA for use in pediatric patients
Omeros Corporation (OMER) announced that the U.S. Food and Drug Administration approved Omeros’ supplemental new drug application following review of efficacy and safety data from a pediatric clinical trial, expanding the indication for OMIDRIA 1% / 0.3% to include use in pediatric patients.
OMIDRIA, used during cataract surgery or intraocular lens replacement, prevents intraoperative miosis and reduces postoperative pain.
FDA approved the sNDA for OMIDRIA under priority review.
The successful clinical trial was conducted in 78 pediatric patients randomized to either OMIDRIA or phenylephrine administered intraoperatively.
Together with the label expansion now including both pediatric and adult patients, FDA also granted OMIDRIA an additional six months of U.S. market exclusivity.
Under section 505A of the Federal Food, Drug, and Cosmetic Act, this six-month extension of market exclusivity is attached to the term of the drug’s patents listed in FDA’s Orange Book.
OMER closed at $18.69. It last traded at $21.50.


To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Leave a Reply

Your email address will not be published. Required fields are marked *